Oral drug trial aims to control blood disorder with fewer side effects
Disease control
Completed
This study tested different low-dose schedules of an oral drug called ASTX727 for adults with lower-risk myelodysplastic syndromes (MDS), a bone marrow disorder that affects blood cell production. The main goals were to find a dose and schedule that is safe and effective at impro…
Phase: PHASE1, PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC